Registration is now open for the CeBIL Annual Symposium 2023 - Intellectual Property & Biologics: Policy Challenges and Responses.
Biologics include some of the most innovative and expensive drugs today. They also raise some of the more complex intellectual property (IP) strategies. Patents provide exclusivity in national markets for the molecules, and trade secrecy shrouds the complex, secret manufacturing processes. Academics, policymakers and industry experts question whether the IP arrangements undermine innovation, efficiency, and competition.
The symposium will focus on important policy issues for pharmaceutical biologics and competitive biosimilars. In particular, it will examine new ideas for innovative partnerships, trade secret disclosure, and evaluation of similarity. We will also consider how the legal architecture both encouraged and impeded the development and manufacturing of COVID-19 vaccines.
For further information and to register to attend, visit CeBIL-2023.eventbrite.co.uk.